Donofrio Joins Neogen Corporation (NEOG) As Director Of Microbiology

LANSING, Mich., Feb. 22, 2016 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that Dr. Robert Donofrio has joined the company as the director of microbiology, research and development in Neogen's Lansing, Mich.-based food safety research and development group.

Dr. Donofrio comes to Neogen after a 16-year tenure at NSF International, an Ann Arbor, Mich.-based safety testing and product certification company. Most recently, Donofrio served as the director of the Applied Research Center at NSF International.

"Dr. Donofrio's extensive professional experience, including strategic partnerships with academia, industry and regulatory bodies, will be strong assets for Neogen as we move forward in the development of innovative microbiological testing products to better serve the needs of the food and consumer goods industries," said Dr. Jennifer Rice, Neogen's vice president of research and development. "We have enjoyed an excellent working relationship with NSF International and Dr. Donofrio over the years, and we are very excited to have the opportunity to strengthen this relationship with the addition of Dr. Donofrio to the Neogen team."

Donofrio will lead a team of 15 research scientists in the development of tests to detect pathogenic bacteria and spoilage organisms. The products include culture media produced in Neogen's facilities in Michigan and England. The company's microbiological products are used in more than 100 countries.

Neogen Corporation develops and markets products dedicated to food and animal safety. The company's Food Safety Division markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases and sanitation concerns. Neogen's Animal Safety Division is a leader in the development of animal genomics along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care and disinfectants.

CONTACT:   
Dr. Jennifer Rice, VP of Research & Development
Neogen Corporation, 517/372-9200

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Harvard scientists showed that a three-gene cocktail, by epigenetic reprogramming, could reverse the aging clock in mice retina nerve cells.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.